Skip Nav Destination
Issues
15 April 2016
-
Cover Image
Cover Image
Expression of NOTCH1 (green) in cancer stem cells isolated from salivary adenoid cystic carcinoma. For details, see the article by Panaccione and colleagues on page 2083 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
CCR Focus
Special Report
Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research
Stephanie R. Land; Benjamin A. Toll; Carol M. Moinpour; Sandra A. Mitchell; Jamie S. Ostroff; Dorothy K. Hatsukami; Sonia A. Duffy; Ellen R. Gritz; Nancy A. Rigotti; Thomas H. Brandon; Sheila A. Prindiville; Linda P. Sarna; Robert A. Schnoll; Roy S. Herbst; Paul M. Cinciripini; Scott J. Leischow; Carolyn M. Dresler; Michael C. Fiore; Graham W. Warren
Cancer Therapy: Clinical
Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Antonio Curti; Loredana Ruggeri; Sarah Parisi; Andrea Bontadini; Elisa Dan; Maria Rosa Motta; Simonetta Rizzi; Sara Trabanelli; Darina Ocadlikova; Mariangela Lecciso; Valeria Giudice; Fiorenza Fruet; Elena Urbani; Cristina Papayannidis; Giovanni Martinelli; Giuseppe Bandini; Francesca Bonifazi; Russell E. Lewis; Michele Cavo; Andrea Velardi; Roberto M. Lemoli
Author Choice
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer
Esme J. Hill; Corran Roberts; Jamie M. Franklin; Monica Enescu; Nicholas West; Thomas P. MacGregor; Kwun-Ye Chu; Lucy Boyle; Claire Blesing; Lai-Mun Wang; Somnath Mukherjee; Ewan M. Anderson; Gina Brown; Susan Dutton; Sharon B. Love; Julia A. Schnabel; Phil Quirke; Ruth Muschel; William G. McKenna; Michael Partridge; Ricky A. Sharma
First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Pamela Munster; Rahul Aggarwal; David Hong; Jan H.M. Schellens; Ruud van der Noll; Jennifer Specht; Petronella O. Witteveen; Theresa L. Werner; E. Claire Dees; Emily Bergsland; Neeraj Agarwal; Joseph F. Kleha; Michael Durante; Laurel Adams; Deborah A. Smith; Thomas A. Lampkin; Shannon R. Morris; Razelle Kurzrock
Author Choice
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Monique B. Nilsson; Uma Giri; Jayanthi Gudikote; Ximing Tang; Wei Lu; Hai Tran; Youhong Fan; Andrew Koo; Lixia Diao; Pan Tong; Jing Wang; Roy Herbst; Bruce E. Johnson; Andy Ryan; Alan Webster; Philip Rowe; Ignacio I. Wistuba; John V. Heymach
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock; Todd A. Alonzo; Robert B. Gerbing; Susana C. Raimondi; Betsy A. Hirsch; Lillian Sung; Jessica A. Pollard; Richard Aplenc; Michael R. Loken; Alan S. Gamis; Soheil Meshinchi
Personalized Medicine and Imaging
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Paraskevi Miltiades; Eleftheria Lamprianidou; Theodoros P. Vassilakopoulos; Sotirios G. Papageorgiou; Athanasios G. Galanopoulos; Christos K. Kontos; Panagiotis G. Adamopoulos; Evangelia Nakou; Sofia Vakalopoulou; Vassilia Garypidou; Maria Papaioannou; Evdoxia Hatjiharissi; Helen A. Papadaki; Emmanuil Spanoudakis; Vassiliki Pappa; Andreas Scorilas; Constantinos Tsatalas; Ioannis Kotsianidis; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group; on behalf of the Hellenic MDS Study Group
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Heidrun Gevensleben; Dimo Dietrich; Carsten Golletz; Susanne Steiner; Maria Jung; Thore Thiesler; Michael Majores; Johannes Stein; Barbara Uhl; Stefan Müller; Jörg Ellinger; Carsten Stephan; Klaus Jung; Peter Brossart; Glen Kristiansen
Cancer Therapy: Preclinical
Author Choice
AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
Fernando Doñate; Arthur Raitano; Kendall Morrison; Zili An; Linnette Capo; Hector Aviña; Sher Karki; Karen Morrison; Peng Yang; Jimmy Ou; Ryuichi Moriya; Yuriy Shostak; Faisal Malik; Rossana Nadell; Wendy Liu; Daulet Satpayev; John Atkinson; Ingrid B.J. Joseph; Daniel S. Pereira; Pia M. Challita-Eid; David R. Stover
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Zachary S. Zumsteg; Natasha Morse; Gabriel Krigsfeld; Gaorav Gupta; Daniel S. Higginson; Nancy Y. Lee; Luc Morris; Ian Ganly; Stephan L. Shiao; Simon N. Powell; Christine H. Chung; Maurizio Scaltriti; José Baselga
Biology of Human Tumors
An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
Vasilis Bikos; Maria Karypidou; Evangelia Stalika; Panagiotis Baliakas; Aliki Xochelli; Lesley-Ann Sutton; George Papadopoulos; Andreas Agathangelidis; Evdoxia Papadopoulou; Zadie Davis; Patricia Algara; George Kanellis; Alexandra Traverse-Glehen; Manuela Mollejo; Achilles Anagnostopoulos; Maurilio Ponzoni; David Gonzalez; Sarka Pospisilova; Estella Matutes; Miguel Angel Piris; Theodora Papadaki; Paolo Ghia; Richard Rosenquist; David Oscier; Nikos Darzentas; Dimitrios Tzovaras; Chrysoula Belessi; Anastasia Hadzidimitriou; Kostas Stamatopoulos
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML
Irina Sadovnik; Andrea Hoelbl-Kovacic; Harald Herrmann; Gregor Eisenwort; Sabine Cerny-Reiterer; Wolfgang Warsch; Gregor Hoermann; Georg Greiner; Katharina Blatt; Barbara Peter; Gabriele Stefanzl; Daniela Berger; Martin Bilban; Susanne Herndlhofer; Heinz Sill; Wolfgang R. Sperr; Berthold Streubel; Christine Mannhalter; Tessa L. Holyoake; Veronika Sexl; Peter Valent
Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling
Lindsey E. Romick-Rosendale; Elizabeth E. Hoskins; Lisa M. Privette Vinnedge; Grant D. Foglesong; Marion G. Brusadelli; S. Steven Potter; Kakajan Komurov; Samantha A. Brugmann; Paul F. Lambert; Randall J. Kimple; Elizabeth L. Virts; Helmut Hanenberg; Maura L. Gillison; Susanne I. Wells
NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Alex Panaccione; Michael T. Chang; Beatrice E. Carbone; Yan Guo; Christopher A. Moskaluk; Renu K. Virk; Luis Chiriboga; Manju L. Prasad; Benjamin Judson; Saral Mehra; Wendell G. Yarbrough; Sergey V. Ivanov
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.